Qatar

The primary regulatory authority for health products in Qatar is the Ministry of Public Health (MOPH), operating through its Medical Supply Department and the Pharmacy and Drug Control Department. The overarching legislative framework is anchored in Law No. 8 of 1969 on the Practice of Pharmacy and related ministerial decrees, supplemented by more recent executive regulations governing medical devices, diagnostics, and digital health solutions. All health products intended for the Qatari market must obtain official registration or marketing authorization from the MOPH prior to importation, distribution, or sale. The approval process generally involves a structured dossier submission, technical evaluation by MOPH reviewers, and in some cases a conformity assessment or inspection step before final authorization is granted.

Applicants are required to appoint a locally registered pharmaceutical or medical device agent as the authorized in-country representative, who assumes regulatory and legal responsibility for the product on the Qatari market. Dossier submissions are expected to align with internationally recognized standards, including the Common Technical Document (CTD) format for pharmaceuticals, and conformity with ISO 13485 and relevant IEC/ISO standards for medical devices. Qatar increasingly references the regulatory decisions of stringent authorities such as the US FDA, EMA, and Gulf Cooperation Council (GCC) member states, and may grant expedited review for products already approved by these bodies. Notable recent reforms include the adoption of the GCC Unified Regulatory Framework for pharmaceuticals and medical devices, alignment with the Gulf Health Council (GHC) technical guidelines, and a strengthened post-market surveillance mandate requiring periodic safety updates and adverse event reporting from registered product holders.

Public procurement of health products in Qatar is highly centralized and predominantly state-driven, reflecting the country's single-payer, government-funded healthcare model. The MOPH Medical Supply Department serves as the principal procurement body for the public sector, managing tenders and supply agreements for hospitals and primary healthcare facilities operated by Hamad Medical Corporation (HMC) and the Primary Health Care Corporation (PHCC). Procurement is conducted through formal competitive tendering processes governed by Law No. 24 of 2015 on public tenders and auctions, administered in coordination with the Ministry of Finance. Framework agreements and long-term supply contracts are common for high-volume consumables, pharmaceuticals, and capital medical equipment, with HMC often issuing its own specialized tenders for advanced medical technologies and digital health infrastructure.

The private healthcare sector in Qatar, while growing with the expansion of facilities such as Sidra Medicine and various private hospital groups, procures health products through independent commercial channels and direct supplier negotiations, often referencing MOPH-registered products as a baseline requirement. Qatar's high per-capita income and strong government financing mean that donor-funded procurement channels such as UNICEF Supply Division, the Global Fund, USAID, or Gavi play no material role in the local market. However, Qatari government entities and foundations, including Qatar Fund for Development, are active donors in global health initiatives, which can create indirect engagement opportunities. Local manufacturing capacity remains limited, but Qatar's National Vision 2030 and associated health strategies include ambitions to develop domestic pharmaceutical and medical technology production, and preferential consideration may be given to products manufactured or assembled locally or within GCC member states as these policies mature.